Targeting PAK5 may provide a new therapeutic approach for endometriosis

Targeting PAK5 may provide a new therapeutic approach for endometriosis

Endometriosis, a prevalent gynecological disease, is characterized by the growth of endometrial-like tissues outside the uterus, resulting in severe pain and infertility in affected women. The pathogenesis of endometriosis remains elusive and effective treatments are limited, highlighting the need for a deeper understanding of its molecular mechanisms. A central role for p21-activated kinase 5 (PAK5) in endometriosis progression has been discovered, demonstrating that PAK5-mediated phosphorylation of pyruvate kinase M2 (PKM2) is critical for anaerobic glycolysis in endometriotic cells. This discovery provides new insights into the pathophysiology of the disease and suggests potential therapeutic targets.

The study looked at the role of PAK5 in endometriosis and examined its effects on cellular functions such as proliferation, migration and invasion. PAK5 was found to enhance these abilities in endometrial epithelial cells, indicating its role in disease progression. Research further investigated the interaction between PAK5 and PKM2, an enzyme integral to glycolytic activity. The increased levels of PKM2 in cancer cells are well documented, but its post-translational modification in endometriosis has been less studied. This study fills the gap by showing that PAK5 promotes PKM2 protein stability through phosphorylation at the SER519 site, suggesting a potential mechanism for PAK5 action in endometriosis.

The experiments performed included cell culture manipulations, tissue collection, and immunohistochemical analyzes to evaluate the expression and activity of PAK5 and PKM2. The results showed that PAK5 overexpression increased PKM2 protein levels and activity, resulting in enhanced glycolysis and endometriotic cell growth. Conversely, PAK5 knockdown reduced PKM2 levels and cellular capabilities, implicating PAK5 as a positive regulator of endometriosis. The study also used a small molecule PAK inhibitor, GNE 2861, to inhibit endometriosis cell proliferation and migration, further supporting the significance of the PAK5-PKM2 axis in endometriosis.

The results of this research highlight the importance of PAK5 in endometriosis and highlight its potential as a therapeutic target. By targeting PAK5, it may be possible to modulate PKM2 activity and subsequently influence anaerobic glycolysis, a critical process in endometriosis. This study's contributions to the field are significant, not only advancing the understanding of endometriosis pathophysiology, but also paving the way for the development of targeted therapies that could improve the treatment landscape for women suffering from this debilitating condition.

Sources: